课题基金 / 基金详情

DSEN Pharmacogenomics of Adverse Reaction Events National Team (DSEN-PREVENT)

DSEN Pharmacogenomics of Adverse Reaction Events National Team (DSEN-PREVENT)
DSEN 不良反应事件药物基因组学国家小组 (DSEN-PREVENT)
批准号：
314437
负责人：
Kim Richard B
金额：
$54.64万
依托单位：
London Health Sciences Centre Res. Inc. (Ont.)
依托单位国家：
加拿大
项目类别：
Directed Grant
财政年份：
2014
资助国家：
加拿大
项目状态：
已结题
起止时间：
2014-05-01 至 2017-05-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=314437&lang=en
关键词：
Adverse Drug Reactions Drug Metabolism Pharmacogenomics Pharmacokinetics Pharmacology

项目摘要

项目成果

Kim Richard B的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Adverse drug reactions (ADRs), including lack of efficacy as well as toxicity, remains one of the leading causes of death and hospitalization for Canadians. Individual patient variability in drug metabolism genes is a major contributor to the development
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Organic Anion Transporting Polypeptide (OATP), P-glycoprotein (P-gp), and Breast Cancer Resistance Protein (BCRP) transporters modulate tamoxifen response during breast cancer therapy
  • 批准号：
    452037
  • 项目类别：
    Operating Grants
  • 资助金额：
    $47.93万
  • 财政年份：
    2021
  • 负责人：
    Kim Richard B
  • 依托单位：
    University of Western Ontario
Integrated Precision Medicine Technology and Approach for Optimal Drug Therapy for Canadians
Clinical and pharmacogenomic predictors of inter-patient variation in direct acting oral anticoagulant (DOAC) plasma concentrations in real-world patients
  • 批准号：
    338124
  • 项目类别：
    Miscellaneous Programs
  • 资助金额：
    $36.24万
  • 财政年份：
    2015
  • 负责人：
    Kim Richard B
  • 依托单位：
    University of Western Ontario
Best Brains Exchange: ''Canada as a Leader in the Development and Deployment of Precision/Personalized Medicine'' March 23, 2015 in Ottawa, ON.
海外基金